NeuExcell Therapeutics raises $10+ million series Pre-A round

NeuExcell Therapeutics, a gene therapy company focusing on neurodegenerative diseases, has announced a $10+ million Series Pre-A financing round. The round was led by Co-Win Ventures, joined by other institutional investors YuanBio, Oriza Seed, Tsingyuan and InnoAngel.

“We are honored to have this highly reputable group of investors join us,” stated Peter Tombros, Board Chair at NeuExcell Therapeutics. “The investors’ experience and support will enable the Company to leverage our proprietary neuroregenerative gene therapy platform across multiple neurodegenerative indications. The strength of this financing validates the Company’s strategy and further validates our science within the biotech industry.”

“We are so excited about the prospects of accelerating our innovative technology to bring effective therapies to millions of patients around the world,” said Professor Gong Chen, the company’s co-founder and chief scientific advisor. “There is a desperate need for breakthrough therapies like ours.”

“We view this as a great opportunity to invest in experienced leadership,” stated Dr. Xin Huang, managing partner at Co-Win Ventures. “NeuExcell’s proprietary technology has the potential to serve as a platform to treat many neurodegenerative diseases, offering hope to groundbreaking new therapies to patients without adequate options today.”

With the closure of this successful Pre-A round, the Company welcomes Dr. Xin Huang and Jonathan Sun to the Board of Directors. PR Newswire